Although patients with cystic fibrosis (CF) experience many symptoms and impaired quality of life, little is known about existential distress. This multivariable logistic regression evaluated the relationship between symptom burden and five existential needs representing existential distress in 164 adults with CF. Eleven percent of participants reported no symptom burden, 61% mild burden, and 28% moderate/severe burden. The most prevalent existential needs were fears about CF worsening (50%) and uncertainty about the future (39%). Participants with moderate/severe symptom burden were likelier to report needing support with all five needs than participants with no or mild burden. For each six-point increase in burden, there was an increased odds of reporting need for support with learning to feel in control, feelings about death and dying, fears about CF worsening, uncertainty about the future, and concerns about worries of others. CF-specific palliative care support based on these prevalent unmet existential needs should be developed and provided.
Keywords cystic fibrosis, palliative care, symptom burden, needs assessment, psychosocial needs Cystic fibrosis (CF) is a chronic, progressive, and ultimately fatal genetic disease affecting more than 30,000 individuals in the United States, with 1,000 additional individuals diagnosed annually. As a multisystem disease, CF not only affects the lungs but also affects the pancreas, liver, and gastrointestinal tract. Previously, CF was a childhood disease, with death from respiratory failure occurring by adolescence. However, as treatment for CF has improved, average life expectancy has increased; today, 85% of people with CF reach adulthood, and the average predicted survival for people with CF born in the United States from 2013 to 2017 is 44 years (Cystic Fibrosis Foundation, 2017) .
Although life span has increased, CF remains a complex, difficult condition to manage, and individuals with CF are burdened by the daily effects of their disease. These individuals experience high physical symptom burden (e.g., dyspnea, fatigue, pain) that significantly impairs their functional status and quality of life (Chen, Killeen, Peterson, Saulitis, & Balk, 2017; Dellon et al., 2010; Friedman et al., 2018; Knudsen et al., 2016; Quittner, Saez-Flores, & Barton, 2016; Sawicki, Sellers, & Robinson, 2008; Stenekes et al., 2009 ). In addition, psychological symptoms are prevalent in this population; rates of depression and anxiety have been found to be two to three times higher among people with CF than in community samples (Quittner et al., 2014; Quittner et al., 2016; Sawicki et al., 2008) . Finally, treatment burden in this population is immense; adults spend a mean of 108 minutes per day on treatments including airway clearance, inhaled and nebulized medications, pancreatic enzyme replacement, and nutritional monitoring (Sawicki, Sellers, & Robinson, 2009 ).
Existential Distress of Adults With CF Unknown
Although the physical and psychological burdens of CF are well documented, the existential distress of this population remains unknown. Existential distress is a broad concept that refers to questions of value and purpose in one's life; it is related to loss of personal meaning, fear of death, fear of being a burden to others, and loss of dignity (Boston, Bruce, & Schreiber, 2011) . Existential distress is common in both patients with, and survivors of, cancer (Posluszny et al., 2016; Vehling & Philipp, 2018) . Furthermore, in patients with cancer, both physical and psychological symptoms have been shown to be associated with components of existential distress, such as demoralization and loss of dignity (Oechsle, Wais, Vehling, Bokemeyer, & Mehnert, 2014; Vehling et al., 2012) . As oncologic treatments and outcomes have improved, cancer has evolved into a chronic, burdensome, progressive disease with similarities to CF; therefore, it is probable that existential distress is also prevalent in individuals with CF.
Although likely prevalent, existential distress may be a topic that clinicians have difficulty broaching with their patients. Because symptom burden in CF is well documented, an association between burden and existential distress-as is seen in patients with cancer-could serve to assist clinicians in identifying their patients experiencing existential distress by way of noticing those who are symptomatic. Clinicians could then provide their most symptomatic (and distressed) patients with the additional psychosocial support they need to help manage the existential questions of value and purpose in their lives. This support could be provided through palliative care, an interdisciplinary approach to care with the goal to improve quality of life and alleviate suffering in those living with serious illness.
Purpose
The goals of this study were twofold: to determine the prevalence of existential distress in individuals with CF by identifying unmet existential needs and to investigate potential associations between symptom burden and these unmet needs in this population.
Method

Study Design and Participants
We recruited a convenience sample of English-speaking patients, aged 18 years or older, at a large, multidisciplinary CF center that includes pulmonologists, nurses, dieticians, social workers, and respiratory therapists who specialize in CF care; the center treats more than 200 patients annually. All eligible patients were approached for voluntary participation by a trained research assistant during scheduled clinic visits between December 2014 and August 2015; there was no incentive for participation. We did not record reasons for refusing participation. Survey data were collected on tablet computers at point of care and directly stored in Research Electronic Data Capture (REDCap), a secure, web-based application designed to support data capture for research studies. These data were originally collected as part of a quality improvement project, which was approved by the Quality Improvement Review Committee. We subsequently received approval from the Institutional Review Board (IRB #PRO16070142) to deidentify the data set and perform cross-sectional analyses, including the present analysis.
Measures
Key independent variable. Symptom burden was assessed using the Edmonton Symptom Assessment System (ESAS). The ESAS evaluates the severity of nine symptoms, each scored from 0 (no symptom) to 10 (worst possible symptom); moderate-to-severe symptoms are defined as ≥4/10 ( Hui & Bruera, 2017 ). An ESAS total distress score was calculated for each participant as a sum of their raw responses to the nine items (potential range = 0-90). The total distress score is categorized as no symptom burden (0), mild (1-30), moderate (31-70), or severe (71-90). Due to sample size, the moderate and severe symptom burden subgroups were combined (i.e., distress score of 31-90). Although this is the first time to our knowledge that the ESAS has been used in individuals with CF, it is widely used in oncology research, and reliability is well established in patients with cancer (Bruera, Kuehn, Miller, Selmser, & Macmillan, 1991; Hui & Bruera, 2017) .
Key dependent variables.
We assessed existential distress using five items from the Supportive Care Needs Survey-Short Form 34 (SCNS-34), an instrument originally designed to measure the perceived needs of patients with cancer (Boyes, Girgis, & Lecathelinais, 2009 ). In the SCNS-34, respondents indicate their level of need for help with 34 items across five domains (psychological, health system and information, physical and daily living, patient care and support, and sexuality) using a 5-point Likert-type scale. An answer of 1 is defined as having no need, an answer of 2 is defined as having a need that was satisfied, and an answer of 3, 4, or 5 is defined as having some degree of distress and current unmet need. As has been done previously in uses of the SCNS-34 in other conditions-such as cardiovascular diseases-we minimally reworded three items to be relevant to CF (see Table 1 ; Kohlmann, Kilbert, Ziegler, & Schulz, 2013) . Although the SCNS-34 has not previously been used in the CF population, it is the most widely-used and comprehensive supportive care needs assessment tool in the literature and is well validated in oncology.
In this study, we used five specific SCNS-34 items in the psychological domain to represent existential distress: fears about my CF getting worse ("worsening"), learning to feel in control of your situation ("control"), uncertainty about the future ("future"), feelings about death and dying ("death"), and concerns about the worries of those close to you ("worries of others").
We ensured these five items had face validity to represent aspects of the concept of existential distress by pretesting with CF clinicians, palliative care researchers, and four patients with CF to ensure comprehension and relevance of items. Furthermore, because these existential needs are not symptom focused, we avoid multicollinearity when comparing symptom burden with these needs.
Clinical variables.
We accessed the electronic medical record for the clinical measures used in this analysis, such as body mass index (BMI), forced expiratory volume in one second (FEV 1 ) at the time of visit, and number of hospitalizations in prior 12 months.
Statistical Analysis
Descriptive statistics were used to summarize the demographic and clinical characteristics of the study population and to describe the prevalence of individual symptoms, overall symptom burden, and unmet existential needs. Using multivariable logistic regression, we estimated the relationship between symptom burden, measured by ESAS total distress score, and existential needs, controlling for age, sex, FEV 1 as a measure of lung function, BMI as a marker of nutritional status, and number of pulmonary exacerbations in the preceding year. These variables in the model were selected based on clinical relevance. Odds ratios (ORs) and 95% confidence intervals (CIs) are presented. To assist with clinical interpretability, the ESAS distress score was rescaled at six-point intervals, the minimal clinically important difference (Hui et al., 2016) . All statistical analyses were performed using Stata version 12. 
Results
Demographics
We surveyed 164 patients from the adult CF center (71% of center population at the time of data collection; Table 2 ). The median age was 29 years (range = 18-66 years), and 56% of participants were male. The median FEV 1 was 57% predicted (range = 16%-110%). Figure 1 . Symptom prevalence among a clinic-based sample of adults with cystic fibrosis.
Note. Any symptom = ESAS score of ≥1/10; moderate-to-severe symptom = ESAS score of ≥4/10. 
Prevalence and Burden of Symptoms
Individual symptom prevalence in this population ranged from 41% (nausea) to 85% (fatigue), whereas moderate-to-severe symptom prevalence ranged from 16% (nausea) to 56% (fatigue). Fatigue (56%), dyspnea (37%), drowsiness (29%), appetite (28%), pain (27%), and anxiety (26%) were the most commonly reported moderate-to-severe symptoms (see Figure 1) . ESAS total distress score ranged from 0 to 75 out of a possible 90. The median distress score was 15/90, representing a mild symptom burden. Eleven percent of participants reported no symptom burden (ESAS distress score of zero), 61% of participants reported a mild symptom burden (score of 1-30), 27% of participants reported a moderate symptom burden (score of 31-70), and 1% of participants reported a severe symptom burden (score of 71-90; see Table 3 ). 
Prevalence of Unmet Existential Needs
Prevalence of self-reported unmet existential needs ranged from 50% ("worsening") to 24% ("death"; see Figure 2 ). Thirty-nine percent of this population reported needing additional support with "future," 34% with "worries of others," and 29% with "control." These data demonstrate that half of participants report needing additional support with "fears about my CF getting worse," and approximately one quarter to one third of participants report needing support with each of the other four existential needs.
Symptom Burden and Unmet Existential Needs
Overall, participants with higher symptom burden reported more unmet existential needs (see Figure 3) . Participants with moderate/severe symptom burden were significantly more likely to report needing support with each of the five existential needs than those with no symptom burden or mild symptom burden (p < .001). For participants with no symptom burden (n = 18), prevalence was 6% (n = 1) for each of the five unmet needs. In those with mild symptom burden (n = 100), prevalence of unmet needs ranged from 14% ("death") to 44% ("worsening"). In the population with moderate/severe symptom burden (n = 46), prevalence ranged from 54% ("death") to 80% ("worsening").
Multivariable Analysis
For each six-point increase in symptom burden, there was an increased odds of reporting unmet need for all items analyzed: "control" ( Table 4 ). These data demonstrate that symptom burden is associated with these unmet existential needs among adults with CF. In addition, FEV 1 was inversely associated with odds of reporting need for support for one item: "worsening" (OR = 1.59, 95% CI = [1. 03, 2.45] ). This OR is higher than any of those for symptom burden. There were no significant increased odds for reporting need for support associated with age, gender, number of pulmonary exacerbations, or BMI.
Discussion
In this study of adults with CF, we found associations between severity of symptom burden and unmet needs related to existential distress. Half of this population reported needing additional support with "fears about my CF getting worse," more than one third with "uncertainty about the future" and "concerns about the worries of those close to you," and more than one fifth with "learning to feel in control of your situation" and "fears about death and dying." Given that providing support for existential distress is a fundamental component of palliative care, this association demonstrates the importance of offering palliative care to the most burdened patients with CF. In addition, given the prevalence of existential concerns in this population, future CF-specific palliative care initiatives should consider providing enhanced psychological support for patients who are struggling to answer the difficult, complex questions about their futures. Our study specifically demonstrated an association between severity of symptom burden and perceived unmet existential needs, suggesting a need for increased palliative care delivery among the most burdened patients with CF. For individuals with moderate-to-severe symptom burden, prevalence of unmet needs ranged from 54% to 80%; thus, for each item, at least half of participants reported needing additional help. For each clinically significant increase in symptom burden, multivariable analysis also demonstrated increased odds of reporting need for support for each item analyzed.
The demonstrated association between symptom burden and unmet existential needs in this population indicates that the effects of an increased symptom burden are not only related to the symptoms themselves. Instead, these symptoms seem to be influencing other, more psychosocial, existential needs related to issues such as the future and relationships with others. Thus, the subjective symptom burden of this population seems to be translating to a higher existential burden. Individuals with a higher symptom burden may be more worried about the future, and thus report more unmet existential needs.
Conversely, our multivariable analysis did not find increased odds of reporting need for support with any of the five existential needs for age, gender, number of pulmonary exacerbations in prior year, or BMI, and FEV 1 -an objective clinical measure of lung function-was inversely associated with odds of reporting need for support for only one item, "fears about my CF getting worse." Therefore, as their disease worsens, patients desire more help with the existential fear of continuing disease progression; in this situation, it appears that these patients recognize their clinical worsening and desire increased support. However, it is somewhat surprising that unlike self-reported symptom burden, poorer lung function-as determined by an objective clinical test-does not lead to increased odds of reporting need for support with more than this single existential need, although the other needs analyzedsuch as "fears of death and dying" and "uncertainty about the future"-are also inherently related to disease progression. Based on this analysis, it seems that desire for increased existential support in individuals with CF is driven by subjective, rather than objective, measures. For these more burdened patients, their symptoms may be providing them with alarming clues about their health status, leading them to desire greater existential support.
These burdened patients with CF require increased support for their unmet existential needs, and we believe that palliative care offers a possible mechanism to provide this support. Given the workforce limitations in palliative care, one possible method of providing this support to individuals with CF is the generalist plus specialist model (Quill & Abernethy, 2013) . In this model, the CF clinician manages many of the patients' more routine palliative needs, initiating referral to specialist palliative care for more complex or refractory problems. It is likely that the existential, psychosocial needs described by the most burdened patients would require this specialist palliative care support. Furthermore, our research demonstrates that high self-reported symptom burden may be one possible trigger for this specialist support.
Although we theorize that this model of palliative care would provide support for the existential distress prevalent in adults with CF, at present, palliative care is both underutilized and understudied in this population. In fact, a 2016 systematic review summarizing nearly 40 years of randomized clinical trials of palliative care interventions found no evidence in genetic disorders, such as CF (Kavalieratos et al., 2016) . Although CF-specific palliative care programs are now beginning to be piloted, there remains a knowledge gap in both program design and patient outcomes of CF-specific palliative support (Bourke et al., 2016) . To date, one nonrandomized observational study of palliative care in adults with CF found that CF care team members believed the addition of palliative care to be helpful; however, this study did not measure patient outcomes (Karlekar, Doherty, Guyer, & Slovis, 2015) . In addition, preliminary evidence from a recent pilot randomized clinical trial shows patient-perceived benefits of embedded specialist palliative care in a CF clinic (Kavalieratos et al., 2019) . However, a Phase III efficacy trial is needed to establish whether palliative care does definitively confer benefits in CF, which program model provides the greatest benefits, and whether these benefits extend to the existential distress prevalent in this population.
There are limitations to this study. The SCNS-34 has not been previously validated for the CF population. However, it is the most comprehensive supportive care needs tool in the palliative care literature, and it has been validated in other populations with chronic diseases (Cheng, Darshini Devi, Wong, & Koh, 2014; Hall et al., 2012; Henry et al., 2014; Kohlmann et al., 2013; Watson et al., 2016) . Using a similar process to those studies, we made very minimal wording changes to make the SCNS-34 relevant to a CF population, which we pretested with patients with CF, clinicians, and palliative care researchers to ensure item comprehension and face validity with these groups, as well as to estimate participant burden. Furthermore, the ESAS is not a CF-specific tool, and may overlook symptoms relevant to this population, such as coughing. The minimal clinically important difference of the ESAS was also determined among patients with cancer, rather than patients with CF (Hui et al., 2016) . Because this was a convenience sample, there may also have been a selection bias with which patients chose to complete the surveys. However, because 71% of the clinic population completed these surveys, selection bias should be minimal. In addition, individuals' clinical status at time of participation may have affected their present perspective, and thus their determination of need for additional support. Finally, because this was a cross-sectional study, it does not evaluate how symptom burden or unmet existential needs change during disease progression; also, causality cannot be determined.
Our results demonstrate that adults with CF have significant unmet, non-symptom-focused existential needs and that these needs are most prevalent in people with higher symptom burden. For these individuals, their subjective symptom burden seems to be translating to a higher level of existential distress and increased desire for support to navigate their existential needs. Many of these people with CF are undeniably burdened by their disease; palliative care is a currently underutilized and understudied approach to meeting their existential needs. CF clinicians and palliative care providers should begin to develop and provide CF-specific palliative care support for their most burdened patients based on the prevalent unmet existential needs in this population to improve quality of life and minimize existential distress.
